Summary
77 / 100 · Bulios Score
What speaks for it
- It holds more cash than debt: Rp 5.37T against Rp 1.21T.
- The share price is below the Bulios Fair Price.
- Earnings per share grew by 12% a year over the last 3 years.
What to watch
None of the indicators we track raises a caution right now.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapPrice against the Bulios Fair Price
P/E against the industry (Medical - Distribution)
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 7.9 IDR for 1 IDR of yearly profit.
Valuation in detailIs it growing?
SlowlyRevenue (IDR)
Diluted EPS (IDR)
Revenue grew by 5.0% a year over 5 years. Over the last 3 years it grew by 4.6% a year. Earnings per share grew by 12% a year over the last 3 years.
Growth in detailDoes it make money?
ReasonablyWhere 100 IDR of revenue goes
- Cost of sales 63 IDR
- Research and development 0.0 IDR
- Sales and administration 26 IDR
- Taxes and other 1.0 IDR
- Net profit 10 IDR
Net profit, industry median (Medical - Distribution) 32 IDR
Out of every 100 IDR of revenue, 10 IDR is left as net profit.
Profitability in detailIs it financially healthy?
YesIt could repay all its debt from a single year of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
Small, safe- Yield
- 1.92%
- Paid out of profit
- 15%
You receive Rp 50.00 per share a year. The company covers the payout with ease.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detail